nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—OPRM1—GPCR ligand binding—ADRB3—polycystic ovary syndrome	0.003	0.003	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—polycystic ovary syndrome	0.00297	0.00297	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—LHB—polycystic ovary syndrome	0.00296	0.00296	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—polycystic ovary syndrome	0.00295	0.00295	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00293	0.00293	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—GNAS—polycystic ovary syndrome	0.00293	0.00293	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—polycystic ovary syndrome	0.00291	0.00291	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00291	0.00291	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GNRH1—polycystic ovary syndrome	0.00289	0.00289	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—NPB—polycystic ovary syndrome	0.00286	0.00286	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	0.00285	0.00285	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00282	0.00282	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00282	0.00282	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00282	0.00282	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	0.00279	0.00279	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	0.00279	0.00279	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—SCT—polycystic ovary syndrome	0.00277	0.00277	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00275	0.00275	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	0.00265	0.00265	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00264	0.00264	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	0.00263	0.00263	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	0.00263	0.00263	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—AKR1C1—polycystic ovary syndrome	0.00259	0.00259	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	0.00259	0.00259	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	0.00257	0.00257	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00256	0.00256	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00251	0.00251	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.0025	0.0025	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00249	0.00249	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	0.00248	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—GNAS—polycystic ovary syndrome	0.00248	0.00248	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	0.00246	0.00246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—SULT2A1—polycystic ovary syndrome	0.00242	0.00242	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—polycystic ovary syndrome	0.00239	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00239	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00239	0.00239	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00239	0.00239	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—SULT2A1—polycystic ovary syndrome	0.00238	0.00238	CbGpPWpGaD
Methylnaltrexone—OPRK1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.00234	0.00234	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.00232	0.00232	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00231	0.00231	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00229	0.00229	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00228	0.00228	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00227	0.00227	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00223	0.00223	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—polycystic ovary syndrome	0.0022	0.0022	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.00217	0.00217	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP11A1—polycystic ovary syndrome	0.00214	0.00214	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00213	0.00213	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP11A1—polycystic ovary syndrome	0.00211	0.00211	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00211	0.00211	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00211	0.00211	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00208	0.00208	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00207	0.00207	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.002	0.002	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NPB—polycystic ovary syndrome	0.002	0.002	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—AKR1C3—polycystic ovary syndrome	0.00199	0.00199	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP17A1—polycystic ovary syndrome	0.00199	0.00199	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00198	0.00198	CbGpPWpGaD
Methylnaltrexone—OPRM1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.00198	0.00198	CbGpPWpGaD
Methylnaltrexone—OPRK1—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.00197	0.00197	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP17A1—polycystic ovary syndrome	0.00196	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00196	0.00196	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00194	0.00194	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00193	0.00193	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00192	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00192	0.00192	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00191	0.00191	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00189	0.00189	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00186	0.00186	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00182	0.00182	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00181	0.00181	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.0018	0.0018	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—polycystic ovary syndrome	0.00178	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00178	0.00178	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00177	0.00177	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00176	0.00176	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00176	0.00176	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00175	0.00175	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00169	0.00169	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NPB—polycystic ovary syndrome	0.00169	0.00169	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00168	0.00168	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00167	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRM1—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.00167	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00167	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00167	0.00167	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00164	0.00164	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00162	0.00162	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00161	0.00161	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.0016	0.0016	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP19A1—polycystic ovary syndrome	0.00158	0.00158	CbGpPWpGaD
Methylnaltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00157	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.00157	0.00157	CbGpPWpGaD
Methylnaltrexone—OPRM1—TCR Signaling Pathway—IL6—polycystic ovary syndrome	0.00156	0.00156	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00156	0.00156	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP19A1—polycystic ovary syndrome	0.00155	0.00155	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00154	0.00154	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00153	0.00153	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00152	0.00152	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00151	0.00151	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.0015	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.0015	0.0015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00149	0.00149	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00147	0.00147	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00144	0.00144	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00142	0.00142	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00141	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00141	0.00141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00136	0.00136	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00134	0.00134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00133	0.00133	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00132	0.00132	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.00131	0.00131	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00128	0.00128	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—CYP1A1—polycystic ovary syndrome	0.00127	0.00127	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metapathway biotransformation—CYP1A1—polycystic ovary syndrome	0.00125	0.00125	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00125	0.00125	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00122	0.00122	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00121	0.00121	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.0012	0.0012	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00119	0.00119	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00115	0.00115	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.00113	0.00113	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NMNAT3—polycystic ovary syndrome	0.00112	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.00112	0.00112	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.0011	0.0011	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FST—polycystic ovary syndrome	0.00109	0.00109	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.00108	0.00108	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.00107	0.00107	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LHB—polycystic ovary syndrome	0.00106	0.00106	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00104	0.00104	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00103	0.00103	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPCAT2—polycystic ovary syndrome	0.00102	0.00102	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SUOX—polycystic ovary syndrome	0.00102	0.00102	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.00101	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00101	0.00101	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.001	0.001	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.001	0.001	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000995	0.000995	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000983	0.000983	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.00097	0.00097	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ISYNA1—polycystic ovary syndrome	0.00095	0.00095	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00095	0.00095	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Biological oxidations—POMC—polycystic ovary syndrome	0.000947	0.000947	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000944	0.000944	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000933	0.000933	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000925	0.000925	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FST—polycystic ovary syndrome	0.00092	0.00092	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000915	0.000915	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000911	0.000911	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000908	0.000908	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LHB—polycystic ovary syndrome	0.000898	0.000898	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000877	0.000877	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000864	0.000864	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000852	0.000852	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.00085	0.00085	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000848	0.000848	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000841	0.000841	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.00083	0.00083	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000815	0.000815	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TEAD2—polycystic ovary syndrome	0.000808	0.000808	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1C2—polycystic ovary syndrome	0.000808	0.000808	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000802	0.000802	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000789	0.000789	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000782	0.000782	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000774	0.000774	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.00077	0.00077	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000762	0.000762	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000754	0.000754	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00073	0.00073	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.00072	0.00072	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000701	0.000701	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000701	0.000701	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000689	0.000689	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	0.000677	0.000677	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000676	0.000676	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000669	0.000669	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000654	0.000654	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000652	0.000652	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000649	0.000649	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000644	0.000644	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	0.000642	0.000642	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000638	0.000638	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000617	0.000617	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000613	0.000613	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	0.000612	0.000612	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000612	0.000612	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000593	0.000593	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000593	0.000593	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.00059	0.00059	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.00058	0.00058	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000571	0.000571	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000565	0.000565	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000551	0.000551	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000549	0.000549	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	0.000546	0.000546	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000538	0.000538	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000522	0.000522	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	0.00052	0.00052	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000518	0.000518	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000517	0.000517	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000513	0.000513	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000503	0.000503	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000498	0.000498	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000491	0.000491	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	0.000475	0.000475	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	0.000464	0.000464	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000455	0.000455	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	0.000449	0.000449	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000433	0.000433	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000431	0.000431	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000425	0.000425	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000422	0.000422	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	0.000413	0.000413	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	0.0004	0.0004	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	0.000386	0.000386	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000376	0.000376	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	0.000371	0.000371	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	0.000366	0.000366	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000364	0.000364	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000362	0.000362	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INS—polycystic ovary syndrome	0.00036	0.00036	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000357	0.000357	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000349	0.000349	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000348	0.000348	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	0.000346	0.000346	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	0.00034	0.00034	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000331	0.000331	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000318	0.000318	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000306	0.000306	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INS—polycystic ovary syndrome	0.000305	0.000305	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000295	0.000295	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—TH—polycystic ovary syndrome	0.000295	0.000295	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000294	0.000294	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	0.000287	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.00028	0.00028	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	0.000269	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000267	0.000267	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	0.000241	0.000241	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	0.000229	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000228	0.000228	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000225	0.000225	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	0.000217	0.000217	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	0.000202	0.000202	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000192	0.000192	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	0.000164	0.000164	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	0.000162	0.000162	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—INS—polycystic ovary syndrome	0.000161	0.000161	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—polycystic ovary syndrome	0.000157	0.000157	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—polycystic ovary syndrome	0.000133	0.000133	CbGpPWpGaD
